Advertisement

Leukemia Medications

Here's a list of approved drugs to treat leukemia including acute lymphocytic or lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Inqovi
GENERIC NAME decitabine/cedazuridine
DRUG INDICATION

Inqovi is a combination of two oral chemotherapy drugs, decitabine and cedazuridine, used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.

DRUG Onureg
GENERIC NAME azacitidine
DRUG INDICATION

Onureg (azacitidine) is a nucleoside analog approved for continued treatment of people with acute myeloid leukemia who achieved complete remission following induction chemotherapy.

DRUG Arzerra
GENERIC NAME ofatumumab
DRUG INDICATION

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

DRUG Besponsa
GENERIC NAME inotuzuma ozogamicin
DRUG INDICATION

Besponsa is an antibody-drug conjugate approved for adults with B cell acute lymphoblastic leukemia that does not respond to prior treatment.

DRUG Blincyto
GENERIC NAME blinatumomab
DRUG INDICATION

Blincyto is a si-specific T-cell engager approved for adults and children with B cell acute lymphoblastic leukemia.

DRUG Bosulif
GENERIC NAME bosutinib
DRUG INDICATION

Bosulif is a kinase inhibitor approved for adults with newly diagnosed or previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

DRUG Calquence
GENERIC NAME acalabrutinib
DRUG INDICATION

Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma and as a first-line or subsequent treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

DRUG Campath
GENERIC NAME alemtuzumab
DRUG INDICATION

Campath is a targeted therapy approved for people with B-cell chronic lymphocytic leukemia who were previously treated with other medications. It is no longer commercially available for leukemia, but has been rebranded as Lemtrada for multiple sclerosis.

DRUG Copiktra
GENERIC NAME duvelisib
DRUG INDICATION

Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

DRUG Elzonris
GENERIC NAME tagraxofusp-erzs
DRUG INDICATION

Elzonris is a CD123-directed toxin approved for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare bone marrow and blood disease that can evolve into leukemia.

DRUG Gazyva
GENERIC NAME obinutuzumab
DRUG INDICATION

Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

DRUG Gleevec
GENERIC NAME imatinib
DRUG INDICATION

Gleevec, a kinase inhibitor, was one of the first targeted therapies for cancer treatment. It is approved for many indications including Philadelphia chromosome positive (Ph+) chronic myeloid leukemia and acute lymphoblastic leukemia, chronic eosinophilic leukemia, mastocytosis and gastrointestinal stromal tumor.

DRUG Iclusig
GENERIC NAME ponatinib
DRUG INDICATION

Iclusig is a kinase inhibitor approved for adults with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia or acute lymphoblastic leukemia who can't use other kinase inhibitor medications. It has a specific indication for CML or ALL with a T315I gene mutation.

DRUG Idhifa
GENERIC NAME enasidenib
DRUG INDICATION

Idhifa is an IDH2 inhibitor approved for adults with acute myeloid leukemia with IDH2 mutations that does not respond to prior treatment.

DRUG Imbruvica
GENERIC NAME ibrutinib
DRUG INDICATION

Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia.

DRUG Lumoxiti
GENERIC NAME moxetumomab pasudotox
DRUG INDICATION

Lumoxiti is a CD22-directed toxin approved for adults with hairy cell leukemia that does not respond to prior treatment.

DRUG Mylotarg
GENERIC NAME gemtuzumab ozogamicin
DRUG INDICATION

Mylotarg is a CD33-directed antibody-drug conjugate approved for adults and children with newly diagnosed or relapsed or refractory acute myeloid leukemia.

DRUG Rituxan
GENERIC NAME rituxumab
DRUG INDICATION

Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima and Ruxience are biosimilar medications.

DRUG Rydapt
GENERIC NAME midostaurin
DRUG INDICATION

Rydapt is a kinase inhibitor approved for adults with newly diagnosed acute myeloid leukemia with FLT3 mutations, and for mastocytosis or mast cell leukemia.

DRUG Sprycel
GENERIC NAME dasatinib
DRUG INDICATION

Sprycel is a kinas inhibitor approved for adults and children with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia or acute lymphoblastic leukemia.

DRUG Tasigna
GENERIC NAME nilotinib
DRUG INDICATION

Tasigna is a kinase inhibitor approved for newly diagnosed or previously Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

DRUG Tibsovo
GENERIC NAME ivosidenib
DRUG INDICATION

Tibsovo is an IDH1 inhibitor approved for adults with acute myeloid leukemia with IDH1 mutations that has relapsed or does not respond to prior treatment.

DRUG Venclexta
GENERIC NAME venetoclax
DRUG INDICATION

Venclexta is a BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in previously treated patients, first-line treatment of CLL or SLL in combination with Gazyva (obinutuzumab) and acute myeloid leukemia in patients who can't use intensive chemotherapy.

DRUG Xospata
GENERIC NAME gilteritinib
DRUG INDICATION

Xospata is a kinase inhibitor approved for treatment of adults with relapsed or refractory acute myeloid leukemia with an FLT3 mutation.

DRUG Zydelig
GENERIC NAME idelalisib
DRUG INDICATION

Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.


Advertisement